OTC · SYUP
Anbc, Inc.
$0.00$0.00 (0.0%)
Anbc, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.0% below the high.
Loading market information…
OTC · AIDA · USD
Stock price
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aida Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Aida Pharmaceuticals, Inc., together with its affiliates, operates extensively throughout mainland China, specializing in the entire spectrum of pharmaceutical and genetic product development. This encompasses formulation, clinical trials, regulatory registration, manufacturing, sales, and marketing. The company's diverse product range includes antibiotics, cardiovascular medicines, and anti-cancer drugs. These are available in various forms, such as injectable powders, intravenous liquids, capsules, tablets, and ointments. Notable products feature Etimicin Sulfate, provided as an injectable powder, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Established in 1999, Aida Pharmaceuticals, Inc. is headquartered in Hangzhou, China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Anbc, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.0% below the high.
$0.00$0.00 (0.0%)
Bloomios, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (0.0%)
MJ Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
Wuhan General Group (China), Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
$0.00$0.00 (0.0%)
Upper Street Marketing Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
CEN Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Better Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Panacos Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
